Abbott India Q2 Review - Key Therapies Report Robust Sales Improvement; Positive Outlook: Axis Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Axis Securities Report
Abbott India Ltd. reported revenue growth of 15.9% in Q2 FY22, outpacing the Indian pharma industry growth of 14.6%. It was majorly driven by sales improvement in key therapies such as gasterointestinal (up 39.1% YoY) and hormones (up 22.8% YoY).
Duphaston (gynecological) Q2 FY22 sales stabilised to Rs 297 crore, reporting a growth of 10.4% YoY.
Earlier, Mankind has launched 'Dydrogesterone' in competition with Duphaston which resulted in a decrease in Duphaston sales.
Abbott India’s gross margins improved by 110 basis points due to a richer product mix and pass on the increase in raw material prices. However, Ebitda margins declined by 160 bps to 21.3% due to higher other expenses.
Reported profit after tax at Rs 196 crore grew by 6.5%, though it was impacted by lower other income.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.